Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Continuous treatment with Rebif, Betaferon or Copaxone over at least the past year.
Injections site tolerability issues documented in medical records or by a nurse at inclusion.
Clinically stable (free from relapses and 6-month confirmed disability progression for at least 6 months) while on therapy.
Documented neurological history at least for the year prior to study entry.
Qualification for Avonex® (Avonex Pen) according to the approved indication (Clinical Isolated Syndrome) or Relapsing Remitting Multiple Sclerosis (RRMS).
Acceptance of magnetic resonance imaging.
You may not be if
Patients who have previously entered this study.
Treatment with Avonex during the 12 months prior to the study.
One or more relapses and/or 6-month confirmed disability progression during the 6 months prior to the study.
Patient on Betaferon with Neutralizing Antibodies (NAbs) more than 400 TRU (tenfold reduction units) and patients on Rebif with NAbs with more than 100 TRU.
Secondary progressive multiple sclerosis.
Primary progressive multiple sclerosis.
Pregnancy or breast feeding.
History of severe depression or attempted suicide or current suicidal ideation.
Medical or psychiatric conditions that compromise the ability to give informed consent, to comply with the protocol, or to complete the study.
Uncontrolled seizure disorder.
Myopathy or clinically significant liver disease.
Inability, in the opinion of the principal investigator or staff, to comply with protocol requirements for the duration of the study.
Known hypersensitivity to interferon-beta or other human proteins including albumin.
A history of drug abuse in the 6 months prior to screening.
Treatment with any of the following in the 30 days before day 1: systemic corticosteroids, ACTH, or other investigational drugs.
Participation in any other study involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study.
Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
